Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Division win Oxford Sparks competition to have an animation created about research into Alzheimer's disease.

Before Christmas 2017, Oxford Sparks ran a competition which offered research groups the chance to win an animation about their research. The competition was won by members of the Alzheimer’s Research UK Oxford Drug Discovery Institute – Dr Hazel Hall-Roberts, a neuroimmunology cell biologist, and Keely Jones, the research group administrator – who will receive a bespoke animation to illustrate and explain their research. Alzheimer’s Research UK Oxford Drug Discovery Institute is based within the Nuffield Department of Clinical Medicine. 

The animation will explain the complex elements of Alzheimer's research, and highlight the importance of developing new drugs to treat the disease. The researchers will collaborate with professional animators to produce this short video about their research, and receive a dedicated social media campaign to publicise it. 

The other winner of the competition was Brooke Johnson, who is based in the Department of Earth Sciences in MPLS. 

Oxford Sparks is a public-facing online project that aims to bring alive the University's science research for wider audiences. Through a diverse range of digital content and activities they showcase and explain research, and encourage the public to engage with scientific research. They have already developed several animations with Medical Sciences researchers, and you can see some examples on their website

Find out more (MPLS news item)

 

 

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.